GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Idiopathic Short Stature
Conditions
Idiopathic Short Stature, Self Image
Trial Timeline
Oct 1, 2011 → Nov 1, 2017
NCT ID
NCT01246219About GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment is a approved stage product being developed by Pfizer for Idiopathic Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT01246219. Target conditions include Idiopathic Short Stature, Self Image.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01246219 | Approved | Completed |
Competing Products
20 competing products in Idiopathic Short Stature